<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>S. No</th>
      <th>Type of studies/ tissue type</th>
      <th>Objective</th>
      <th>Species</th>
      <th>No.of Animals</th>
      <th>Total No. of animals in Standard study</th>
      <th>Parameters / End points of In vivo studies</th>
      <th>Parameters/ in vitro end points</th>
      <th>Alternatives if any</th>
      <th>References/ Guidelines</th>
      <th>Commercially available NAMs</th>
      <th>Name of the company</th>
      <th>Website link</th>
      <th>PMID/ material/handout</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
    </tr>
    <tr>
      <td>1.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 400</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>Circulating tumor cell (CTC) on chip</td>
      <td>AZAR</td>
      <td>https://azar-innovations.com/</td>
      <td>Scientific literature / handouts</td>
    </tr>
    <tr>
      <td>2.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 401</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>3D tumoroid</td>
      <td>CelVivo</td>
      <td>celvivo.com</td>
      <td>Scientific literature/ handouts</td>
    </tr>
    <tr>
      <td>3.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 402</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>3D Skin – Tumor on chip</td>
      <td>Tissuse (HUMIMIC)</td>
      <td>https://www.tissuse.com/en/about-us/</td>
      <td>Scientifc literature  / handouts</td>
    </tr>
    <tr>
      <td>4.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 403</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>3D InSight™ Oncology platform- human-derived 3D tumor models</td>
      <td>InSphero</td>
      <td>https://insphero.com/</td>
      <td>Scientifc literature/ handouts</td>
    </tr>
    <tr>
      <td>5.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 404</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>3D Predict™ Glioma- 3D cell culture technology cultivates patients’ live tumor cells in a controlled environment that closely replicates their actual tumor and immune system</td>
      <td>KIYATEC</td>
      <td>https://kiyatec.com/</td>
      <td>Scientfic literature/ handouts</td>
    </tr>
    <tr>
      <td>6.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 405</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>3D cancer spheroid</td>
      <td>Thermo Fisher Scientific</td>
      <td>https://www.thermofisher.com/in/en/home.html</td>
      <td>Scientifc literature/ handouts</td>
    </tr>
    <tr>
      <td>7.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 406</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>SynTumor 3D Cancer Model​ – Recreating The Tumor Microenvironment</td>
      <td>SynVivo</td>
      <td>https://www.synvivobio.com/</td>
      <td>Scientifc literature/ handouts</td>
    </tr>
    <tr>
      <td>8.0</td>
      <td>Carcinogenicity studies</td>
      <td>This study provides information on the possible health hazards likely to arise from repeated exposure for a period lasting up to the entire lifespan of the species used.The study will provide information on the toxic effects of the substance, including potencial carcinogenicity indicate target organs and the possibility of accumulation. It can provide an estimate of the NOAEL for toxic effectsand , in the case of non-genotoxic carcinogens, for tumour responses, which can be used for establishing safety criteria for human exposure.</td>
      <td>Rats/ Mice</td>
      <td>Rodents : 50 / sex / Group</td>
      <td>Rodents - 407</td>
      <td>Target organs neoplasms/Histopathology of target organs/ Clinical biochemistry including hormones</td>
      <td>WoE factors:\n1) HistopathologyCellular hypertrophy\no Cellular hyperplasia\no Persistent tissue injury and/or chronic inflammation\no Pre-neoplastic changes\no Tumors\n2) Hormonal effects\n hormone receptor binding, regulation of\nhormone levelsAtrophy\no Hypertrophy\no Hyperplasia\n3) Secondary PharmacologySelectivity\no Off-target potential\no Carcinogenic risk (e.g., binding to nuclear receptors)\n4) Additional investigative studies or analyses of specimens collected from\nprior studies (e.g., special histochemical stains, molecular biomarkers,\nserum hormone levels, immune cell function, in vitro or in vivo test\nsystems, data from emerging technologies) \n5)  Clinical data generated to inform human mechanistic relevance at\ntherapeutic doses and exposures (e.g., urine drug concentrations and\nevidence of crystal formation, targeted measurements of clinical plasma\nhormonal alterations, human imaging data)</td>
      <td>REDUCTION: In vitro Carcinogenicity tests are available\n  - Syrian hamster embryo (SHE) cells\n  - Cell Transformation assay (CTA)\n  These should not be used as stand alone methods. They should always be used in combination with other complementary information sources.\n  REPLACEMENT EFFORTS: "WoE evidence to assess the relevance of 2 -yr rat study</td>
      <td>Note for Guidance on Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95; ICH S1B (R1))\n In vitro: ADDENDUM to ICH S1B (R1): https://www.fda.gov/media/152777/download ; OECD GD 214, 231; EURL ECVAM recommendation (2012&amp;2013)</td>
      <td>3D  heart-liver-cancer on chip</td>
      <td>Hesperos</td>
      <td>https://hesperosinc.com/</td>
      <td>Scientifc litearture/ handouts</td>
    </tr>
  </tbody>
</table>